Unit for Infection Control and Antimicrobial Stewardship, Visceral, Transplant, Vascular, and Paediatric Surgery, University Hospital of Würzburg, Würzburg, Germany.
Department of General, Visceral, Transplant, Vascular, and Paediatric Surgery, University Hospital of Würzburg, Würzburg, Germany.
Surg Infect (Larchmt). 2022 Jun;23(5):444-450. doi: 10.1089/sur.2021.344. Epub 2022 May 9.
Although abdominal foci are the second most common source of sepsis, only few studies focus on the optimal length of post-operative antibiotic therapy in critically ill patients with abdominal sepsis. The aim of this study was to compare the outcomes of short versus long antibiotic therapy as well as broad-spectrum penicillin versus carbapenem in patients with abdominal sepsis. We performed a single center retrospective study in patients with abdominal sepsis who underwent emergency surgery. The study was conducted in a tertiary hospital in Germany during 2016-2018. We reviewed the duration of post-operative antibiotic therapy and the initially used agent, comparing patients treated shorter or longer than seven days with or without source control. Depending on the empirically given antibiotic, a subgroup analysis was conducted comparing patients treated with piperacillin-tazobactam versus carbapenems. Longer duration of post-operative antibacterial treatment (>7 days) was not substantially advantageous. The group with a longer course of antibiotic therapy had more severe post-operative complications (82.4% [n = 61] vs. 62.5% [n = 20]; p = 0.01) requiring longer critical care support (18 days vs. 11 days; p = 0.027), prolonging the length of stay (28 days vs. 20 days; p = 0.044). Surgical re-interventions were more frequent in the long-course arm (70.3% vs. 40.6%; p = 0.004). The subgroup analysis comparing piperacillin-tazobactam versus carbapenems confirmed more severe complications (86.3% vs. 67.5%; p = 0.04) for the carbapenem arm. Post-surgical continuation of antibiotic agents beyond seven days was observed with more post-operative complications and delayed recovery. Piperacillin-tazobactam seems to be a potent alternative for patients with abdominal sepsis.
虽然腹部病灶是脓毒症的第二大常见来源,但只有少数研究关注腹部脓毒症重症患者术后抗生素治疗的最佳时长。本研究旨在比较腹部脓毒症患者短期与长期抗生素治疗以及广谱青霉素与碳青霉烯类药物的疗效。我们对在德国一家三级医院接受急诊手术的腹部脓毒症患者进行了一项单中心回顾性研究。该研究于 2016 年至 2018 年进行。我们回顾了术后抗生素治疗的时长和最初使用的药物,比较了有或无源头控制的患者接受短于或长于 7 天的治疗。根据经验性给予的抗生素,进行了亚组分析,比较了使用哌拉西林-他唑巴坦与碳青霉烯类药物的患者。术后抗菌治疗的时间延长(>7 天)并没有显著优势。接受更长疗程抗生素治疗的患者术后并发症更严重(82.4%[n=61] vs. 62.5%[n=20];p=0.01),需要更长时间的重症监护支持(18 天 vs. 11 天;p=0.027),住院时间延长(28 天 vs. 20 天;p=0.044)。长疗程组更频繁地进行再次手术干预(70.3% vs. 40.6%;p=0.004)。比较哌拉西林-他唑巴坦与碳青霉烯类药物的亚组分析证实,碳青霉烯类药物组的并发症更严重(86.3% vs. 67.5%;p=0.04)。术后继续使用抗生素超过 7 天的患者术后并发症更多,恢复时间也更长。哌拉西林-他唑巴坦似乎是治疗腹部脓毒症患者的一种有效替代药物。